PMC:7534795 / 1330-1793 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15726","span":{"begin":96,"end":101},"obj":"Body_part"}],"attributes":[{"id":"A40938","pred":"fma_id","subj":"T15726","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":400,"end":408},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T53704","span":{"begin":68,"end":69},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12","span":{"begin":7,"end":11},"obj":"Chemical"},{"id":"T13","span":{"begin":13,"end":16},"obj":"Chemical"},{"id":"T15","span":{"begin":22,"end":42},"obj":"Chemical"},{"id":"T16","span":{"begin":38,"end":42},"obj":"Chemical"},{"id":"T17","span":{"begin":44,"end":47},"obj":"Chemical"},{"id":"T21","span":{"begin":70,"end":75},"obj":"Chemical"},{"id":"T22","span":{"begin":96,"end":101},"obj":"Chemical"},{"id":"T23","span":{"begin":269,"end":274},"obj":"Chemical"},{"id":"T24","span":{"begin":285,"end":296},"obj":"Chemical"},{"id":"T25","span":{"begin":331,"end":336},"obj":"Chemical"},{"id":"T26","span":{"begin":350,"end":358},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A14","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_36006"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A18","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A19","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A20","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":220,"end":418},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}

{"project":"LitCovid-PubTator","denotations":[{"id":"41","span":{"begin":409,"end":417},"obj":"Species"},{"id":"45","span":{"begin":13,"end":16},"obj":"Chemical"},{"id":"46","span":{"begin":22,"end":42},"obj":"Chemical"},{"id":"47","span":{"begin":44,"end":47},"obj":"Chemical"},{"id":"48","span":{"begin":96,"end":101},"obj":"Chemical"},{"id":"49","span":{"begin":265,"end":274},"obj":"Chemical"},{"id":"50","span":{"begin":327,"end":336},"obj":"Chemical"},{"id":"61","span":{"begin":400,"end":408},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D015118"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D004281"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D004281"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D008055"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D015525"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D015525"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"aenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors to a group of potent bioactive lipid mediators, generated endogenously, which mediate many of the beneficial effects attributed to their parent compounds. Considering the favorable safety profile for n-3 PUFAs and their metabolites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of t"}